On March 8, 2026, the China Securities Regulatory Commission (CSRC) website indicated that Citic Securities Company Limited has submitted a filing report for the initial public offering and listing guidance of Balingke Pharmaceutical Technology (Shanghai) Co., Ltd. The guidance institution is Citic Securities Company Limited, the law firm is Jingtian & Gongcheng, and the accounting firm is Rongcheng Accounting Firm (Special General Partnership).

Balingke Pharmaceutical Technology (Shanghai) Co., Ltd., located in Shanghai, is a high-tech group enterprise providing process solutions for the life sciences sector. The company focuses on the research, development, and manufacturing of key process equipment and consumables used in the production of recombinant protein drugs, vaccines, antibody drugs, cell therapies, gene therapies, and other biologics. Its products cover upstream cell culture, single-use formulation and storage systems, downstream chromatography, three filtration steps, hydration products, and process development services. The legal representative is Chen Zhi.

The controlling shareholder and its shareholding percentage in Balingke are as follows: Hainan Balingke Technology Investment Center (Limited Partnership) directly holds 100,068,120 shares, representing a 27.7967% stake, making it the controlling shareholder.

Corporate information reveals that Balingke has historically received investments from institutions including Shenzhen Capital Group, Cathay Capital, Qingsong Capital, and Sherpa Investment.